Європейський Союз - мальтійська - EMA (European Medicines Agency)

viiv healthcare b.v. - fostemsavir trometamol - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine, zidovudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibatteriċi għal użu sistemiku, - tobi podhaler huwa indikat għat-terapija suppressiva ta 'infezzjoni pulmonari kronika minħabba pseudomonas aeruginosa fl-adulti u tfal ta' 6 snin 'il fuq b'fibrożi ċistika. ara t-taqsimiet 4. 4 u 5. 1 rigward data fi gruppi ta 'etajiet differenti. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazole - schizophrenia; bipolar disorder - psikolettiċi - abilify huwa indikat għat-trattament tal-iskiżofrenja fl-adulti u fl-adolexxenti ta '15-il sena jew ikbar. abilify huwa indikat għat-trattament ta 'episodji manijaċi serji f'disturb bipolari i u għall-prevenzjoni ta' episodju manijaku ġdid f'adulti li esperjenzaw episodji predominantament manijaċi u li l-episodji manijaċi rrispondew għat-trattament b'aripiprazole. abilify huwa indikat għat-trattament sa 12-il ġimgħa ta 'episodji manijaċi serji f'disturb bipolari i fl-adolexxenti ta' minn 13-il sena u anzjani.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - l-enżimi - mepsevii huwa indikat għall-kura ta 'manifestazzjonijiet mhux newroloġiċi ta' mucopolysaccharidosis vii (mps vii; hekk syndrome).

Європейський Союз - мальтійська - EMA (European Medicines Agency)

allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - antidiarrheals, intestinali anti-infjammatorji / antiinfective aġenti - truberzi huwa indikat fl-adulti għat-trattament tas-sindromu tal-musrana irritabbli bid-dijarea (ibs d).

Європейський Союз - мальтійська - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). advate ma fihx il-fattur von willebrand fi kwantitajiet farmakoloġiċi effettivi u għaldaqstant mhuwiex indikat fil-mard ta ' von willebrand.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

merial - virus ibr inattivat - immunoloġiċi għall-bovidae - bhejjem - immunizzazzjoni attiva tal-baqar biex tnaqqas is-sinjali kliniċi ta 'rhinotracheitis bovina infettiva (ibr) u l-eskrezzjoni tal-virus tal-kamp. , il-bidu ta 'l-immunità huwa ta' 14-il jum u t-tul ta 'l-immunità huwa ta' 6 xhur.